
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd has demonstrated a positive growth trajectory in its revenue, with fourth-quarter 2025 revenue reaching $174.4 million, reflecting a 4% increase quarter-over-quarter and an 8% increase year-over-year, outperforming prior estimates due to robust domestic sales of Optune Gio. The company is poised for future growth as it has secured national reimbursement in Spain, anticipated to contribute significantly in 2026, and clinical trials like the TRIDENT trial may expand patient eligibility for Tumor Treating Fields (TTFields) technology. Continued positive dynamics in the U.S. market, coupled with enhanced access to glioblastoma treatments through a trained sales force and community centers, indicate a strong outlook for NovoCure’s operational performance.
Bears say
NovoCure Ltd. is facing a negative outlook primarily due to revised revenue forecasts stemming from lackluster performance in its commercial efforts, particularly related to its Optune product line. The company has lowered its 2026 revenue estimates for Glioblastoma (GBM) to $690 million from $702 million, and total revenue estimates have also decreased to $711.3 million compared to a previous estimate of $738.9 million. Furthermore, significant risks such as potential safety concerns, lower-than-expected clinical efficacy, and heightened competition could adversely affect the company's financial performance and market position.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares